Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Three healthcare giants are vying for the prize.

After COVID-19, Could This Be the Next Billion-Dollar Vaccine Market?

BioNTech SE

GlaxoSmithKline

Kadmon Hlds

Novo Nordisk

Pfizer

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.

Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data

Sanofi SA (NASDAQA:SNY) announced that it will be suspending any further developments of its mRNA-based Covid-19 vaccine, despite positive results in its last study, as inoculations from Moderna (MRNA) and Pfizer (PFE) dominate the market.

Sanofi Suspends mRNA Vaccine Development Amid Stiff Competition

The French pharma giant continues work on a recombinant Covid-19 vaccine with GlaxoSmithKline, which is also being evaluated as a booster shot.

A Sanofi Covid Vaccine Had Positive Early Trials. Why Is It Being Shelved?

Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi says that the market is well-served with the dominant role of BioNTech SE (NASDAQ: BNTX) - Pfizer Inc (NYSE: PFE) alliance and Moderna Inc (NASDAQ: MRNA).

Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know

Sanofi Halts Development of Its mRNA Covid-19 Vaccine. The Stock Is Rising.

Bristol-Myers

Vertex Pharmaceuticals

Analysts expect one of them could skyrocket more than 40% over the next 12 months.

3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%

Sanofi is dropping plans for its own mRNA-based COVID-19 vaccine because of the dominant role of the BioNTech-Pfizer alliance as well as Moderna in the fight against the pandemic, the company said on Tuesday.

Sanofi ditches mRNA COVID-19 vaccine amid rivals' success

Sanofi said Tuesday that it recorded positive interim results from an early study into its first mRNA-based Covid-19 vaccine candidate.

Sanofi reports encouraging early results for COVID-19 mRNA vaccine candidate

Sanofi announces p ositive Phase 1/2 study interim results for its first mRNA-based vaccine candidate

Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate

Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Monday after the company scored an analyst upgrade. The Analyst: SVB Leerink analyst Geoffrey Porges upgraded Sanofi from Market Perform to Outperform and raised his price target per U.S. ADR from $69.61 to $71.37.

Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism

British American Tobacco

Diageo

Novartis

Unilever

With September and the third quarter almost over, many investors are looking to the fourth quarter and beyond.

5 European Dividend Aristocrats Offer Huge Income and Growth Potential

Availability of the Q 3 202 1 Memorandum for modelling purposes

Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes

Sanofi is a leading global healthcare company from France. 2021 results are strong, and FY 2021 guidance lifted.

Sanofi: A Wonderful Company At A Fair Price

NEW ORLEANS, Sept. 21, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen.  According to data released at the European Society for Medical Oncology 2021 ( ESMO21 ), Libtayo, used on top of platinum doublet chemotherapy, reduced the risk of death by 29% over chemo alone in patients with previously untreated, advanced non-small cell lung cancer (NSCLC).

Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC

Dynavax Technologies

Inovio Pharmaceuticals

Novavax

Their vaccines could be late to the party. But the stocks might still be big winners.

5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch

AbbVie

There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.

AbbVie's Pain Is Sanofi's and Regeneron's Gain

Sanofi's Covid vaccine is now in its Phase 3 trial, and the pharmaceutical company says results could come by the end of the year.

How a Covid Vaccine Could Lift Sanofi's Stock

Telesis Bio Inc

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed acquisition of the company by Sanofi (NASDAQ: SNY).

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.

Johnson & Johnson

GlaxoSmithKline PLC ( GSK , Financial) is forecasted to carve out more than 25% of a vaccine market that is expected to reach $10.5 billion by 2030. FiercePharma repotrted three other members of big pharma are also in line to be rewarded for developing a shot for respiratory syncytial virus, with Pfizer Inc. ( PFE , Financial) raking in $2.1 billion, Johnson & Johnson ( JNJ , Financial) adding $1.7 billion to its top line and Sanofi SA ( SNY , Financial) pocketing $1.2 billion.

Glaxo, Pfizer, J&J and Sanofi Expected to Grab Biggest Shares of RSV Vaccine Business

Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.

Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study

Sanofi SA's (NASDAQ: SNY) BTK inhibitor, rilzabrutinib, has flunked its first major clinical test. Rilzabrutinib was Principia Biopharma Inc's one of the key candidates that Sanofi acquired last year for $3.68 billion.

News for Sanofi Stock (SNY)